Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report

While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion+ tumors. Both drugs have phase I data, demonstrating...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanman, Tyler, Hayden Gephart, Melanie, Bui, Nam, Toland, Angus, Nagpal, Seema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787578/
https://www.ncbi.nlm.nih.gov/pubmed/35111018
http://dx.doi.org/10.1159/000521158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787578/
https://www.ncbi.nlm.nih.gov/pubmed/35111018
http://dx.doi.org/10.1159/000521158

Ejemplares similares